New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
12:16 EDTTRIP, VRTXStocks with call strike movement; TRIP VRTX
TripAdvisor (TRIP) January 125 call option implied volatility increased 2% to 39, Vertex (VRTX) January 120 call option implied volatility increased 3% to 40 according to IVolatility.
News For VRTX;TRIP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 2, 2015
14:50 EDTVRTXVertex to resume trading at 3:00 PM ET
Subscribe for More Information
14:42 EDTVRTXVertex says 'too early to comment' on international Orkambi pricing
Subscribe for More Information
14:33 EDTVRTXVertex sets Orkambi price at $259,000, sees delivery to pharmacies 'within days'
Following today's confirmation from Vertex that Orkambi has received FDA approval, the company held a conference call providing an update on the drug. Vertex remarked that it is "ready to launch this medicine." Vertex will offer a co-pay assistance program for the drug, with certain eligibility criteria. Company believes it can achieve a similar patient cost situation as Kalydeco. Sets price of Orkambi at $259,000 per year. Expects delivery to pharmacy network "within days."
13:52 EDTVRTXVertex to hold a conference call
Subscribe for More Information
13:47 EDTVRTXVertex confirms FDA approval of ORKAMBI
Vertex Pharmaceuticals announced that the U.S. FDA approved ORKAMBI, the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the F508del mutation. It is only indicated for these patients, who can be identified with a genetic test. People with two copies of the F508del mutation represent the largest group of people with CF. Of the 30,000 people in the United States with CF, approximately 8,500 ages 12 and older have two copies of the F508del mutation. ORKAMBI will be available for shipment to specialty pharmacies in the United States within days.
12:47 EDTVRTXVertex to return to profitability with approval, says Piper Jaffray
Subscribe for More Information
12:00 EDTVRTXVertex receives FDA approval for Orkambi
Subscribe for More Information
11:50 EDTVRTXVertex trading halted, pending news
Subscribe for More Information
June 30, 2015
11:07 EDTTRIPPriceline rises after analysts highlight positive travel trends
Subscribe for More Information
07:41 EDTTRIPOnline travel trends point to solid Q2, says Piper Jaffray
Piper Jaffray analyst Michael Olson said analysis of travel industry trends through May point to a "solid" second quarter for online travel, noting his belief that Priceline (PCLN) has the most favorable risk/reward in the space given the stock's underperformance so far this year. In addition to an Overweight rating on Priceline, Olson keeps an Overweight on HomeAway (AWAY) and TripAdvisor (TRIP), but has a Neutral rating on Expedia (EXPE), citing its relative valuation.
07:32 EDTVRTXVertex should get Orkambi approval by Monday or sooner, says Piper Jaffray
Subscribe for More Information
June 29, 2015
15:28 EDTVRTXVertex management to meet with UBS
Subscribe for More Information
07:47 EDTVRTXCerulean appoints Stuart A. Arbuckle to board of directors, effective June 26
Subscribe for More Information
June 25, 2015
12:59 EDTTRIPOptions with increasing implied volatility
Subscribe for More Information
June 23, 2015
11:00 EDTTRIPOptions with increasing implied volatility
Options with increasing implied volatility:TRIP WPZ CMG BIIB WMB AMZN ISRG VMW
June 22, 2015
10:41 EDTTRIPOptions with increasing implied volatility
Subscribe for More Information
June 19, 2015
14:07 EDTTRIPOptions with increasing implied volatility: NFLX CI TRIP AET
06:17 EDTTRIPEU gives Google critics one month to remark on antitrust charges, Reuters says
European Union antitrust regulators have sent copies of their charges against Google (GOOG) to critics of the company and given them a month to comment on the charges, Reuters reports, citing one of the complainants. Google has been accused by many companies of abusing its market power and cheating consumers and rivals by tweaking search results to favor its shopping service, the report says. 19 companies, including Microsoft (MSFT) and TripAdvisor (TRIP), are expected to receive the EU charge sheet, Reuters says. Reference Link
June 18, 2015
11:31 EDTTRIPOptions with increasing implied volatility
Subscribe for More Information
07:37 EDTTRIPTripAdvisor deal attractive for Marriott, says UBS
UBS said the TripAdvisor (TRIP) deal is attractive for Marriott (MAR) since its adds a new customer acquisition outlet with a flexible partner. The firm also noted fear of further consolidation in the OTA space and the likelihood Marriott is at the low end of the commission scale. UBS reiterated its Neutral rating and $83 price target on Marriott shares.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use